Literature DB >> 20422398

Lymphocytes promote albuminuria, but not renal dysfunction or histological damage in a mouse model of diabetic renal injury.

A K H Lim1, F Y Ma, D J Nikolic-Paterson, A R Kitching, M C Thomas, G H Tesch.   

Abstract

AIMS/HYPOTHESIS: Diabetic nephropathy is an inflammatory disease with prominent leucocyte infiltration of the kidneys. While the importance of macrophages in diabetic renal injury has been clearly demonstrated, the role of lymphocytes is still unknown. We therefore examined the development of diabetic renal injury in lymphocyte-deficient mice.
METHODS: Streptozotocin was used to induce diabetes in Rag1(-/-) mice, which lack mature T and B lymphocytes, and in wild-type (Rag1(+/+) ) controls. The development of renal injury was examined over 20 weeks of diabetes.
RESULTS: Both groups developed equivalent diabetes, however only Rag1(+/+) mice had kidney infiltration with CD4, CD8, CD22 and forkhead box P3-positive cells, as well as glomerular immunoglobulin deposition. At 20 weeks, Rag1(+/+) mice exhibited renal hypertrophy, increased mesangial and interstitial matrix, kidney macrophage accumulation, tubular injury, progressive albuminuria and a decline in renal function. In comparison, diabetic Rag1(-/-) mice showed similar histological damage, matrix expansion, macrophage accrual and loss of renal function, but were protected from increasing albuminuria. This protection was associated with protection against loss of podocytes and glomerular podocin production, and with reduced glomerular macrophage activation. CONCLUSIONS/
INTERPRETATION: These results show that lymphocytes contribute to the development of diabetic albuminuria, which may partly arise from increasing glomerular macrophage activation and podocyte damage. In contrast, lymphocytes do not appear to promote tubular injury, increased matrix deposition or decline in renal function in a mouse model of type 1 diabetes. Our findings suggest that innate immunity rather than adaptive immune responses are the major inflammatory contributor to the progression of diabetic renal injury.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20422398     DOI: 10.1007/s00125-010-1757-1

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  31 in total

1.  Macrophage accumulation in human progressive diabetic nephropathy.

Authors:  Duy Nguyen; Fu Ping; Wei Mu; Prudence Hill; Robert C Atkins; Steven J Chadban
Journal:  Nephrology (Carlton)       Date:  2006-06       Impact factor: 2.506

2.  Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice.

Authors:  F Y Chow; D J Nikolic-Paterson; E Ozols; R C Atkins; B J Rollin; G H Tesch
Journal:  Kidney Int       Date:  2006-01       Impact factor: 10.612

3.  Quantification of renal pathology by image analysis.

Authors:  Gopala K Rangan; Greg H Tesch
Journal:  Nephrology (Carlton)       Date:  2007-12       Impact factor: 2.506

4.  Role of CD8(+) cells in the progression of murine adriamycin nephropathy.

Authors:  Y Wang; Y P Wang; Y C Tay; D C Harris
Journal:  Kidney Int       Date:  2001-03       Impact factor: 10.612

5.  Diabetes mellitus with immune complex glomerulonephritis.

Authors:  S Aziz; A H Cohen; R L Winer; F Llach; S G Massry
Journal:  Nephron       Date:  1979       Impact factor: 2.847

6.  Oxidized LDL-anti-oxidized LDL immune complexes and diabetic nephropathy.

Authors:  D H Atchley; M F Lopes-Virella; D Zheng; D Kenny; G Virella
Journal:  Diabetologia       Date:  2002-10-12       Impact factor: 10.122

7.  Cellular and humoral immune responses in the early stages of diabetic nephropathy in NOD mice.

Authors:  Xiaoyan Xiao; Bin Ma; Baojun Dong; Peng Zhao; Ningwen Tai; Li Chen; F Susan Wong; Li Wen
Journal:  J Autoimmun       Date:  2009-02-05       Impact factor: 7.094

8.  Diabetic nephropathy with superimposed immune complex glomerulonephritis.

Authors:  S G Sabnis; T T Antonovych
Journal:  South Med J       Date:  1983-04       Impact factor: 0.954

9.  Juxtaglomerular apparatus T-cell infiltration affects glomerular structure in Type 1 diabetic patients.

Authors:  R Moriya; J C Manivel; M Mauer
Journal:  Diabetologia       Date:  2003-11-15       Impact factor: 10.122

10.  Activation of mouse peritoneal macrophages by monoclonal antibodies to Mac-1 (complement receptor type 3).

Authors:  A Ding; S D Wright; C Nathan
Journal:  J Exp Med       Date:  1987-03-01       Impact factor: 14.307

View more
  31 in total

1.  Deletion of bone-marrow-derived receptor for AGEs (RAGE) improves renal function in an experimental mouse model of diabetes.

Authors:  Greg Tesch; Karly C Sourris; Shaun A Summers; Domenica McCarthy; Micheal S Ward; Danielle J Borg; Linda A Gallo; Amelia K Fotheringham; Allison R Pettit; Felicia Y T Yap; Brooke E Harcourt; Adeline L Y Tan; Joshua Y Kausman; David Nikolic-Paterson; Arthur R Kitching; Josephine M Forbes
Journal:  Diabetologia       Date:  2014-06-24       Impact factor: 10.122

2.  Increased circulating cytokine levels in African American women with obesity and elevated HbA1c.

Authors:  Ariel Williams; Natasha Greene; K Kimbro
Journal:  Cytokine       Date:  2020-01-28       Impact factor: 3.861

Review 3.  Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targets.

Authors:  Raimund Pichler; Maryam Afkarian; Brad P Dieter; Katherine R Tuttle
Journal:  Am J Physiol Renal Physiol       Date:  2016-08-24

Review 4.  Role of the Immune System in Diabetic Kidney Disease.

Authors:  Fionnuala B Hickey; Finian Martin
Journal:  Curr Diab Rep       Date:  2018-03-12       Impact factor: 4.810

5.  Hyperglycemia and renin-dependent hypertension synergize to model diabetic nephropathy.

Authors:  Bryan R Conway; Jillian Rennie; Matthew A Bailey; Donald R Dunbar; Jonathan R Manning; Christopher O Bellamy; Jeremy Hughes; John J Mullins
Journal:  J Am Soc Nephrol       Date:  2011-12-22       Impact factor: 10.121

6.  The proteoglycan biglycan regulates expression of the B cell chemoattractant CXCL13 and aggravates murine lupus nephritis.

Authors:  Kristin Moreth; Rebekka Brodbeck; Andrea Babelova; Norbert Gretz; Tilmann Spieker; Jinyang Zeng-Brouwers; Josef Pfeilschifter; Marian F Young; Roland M Schaefer; Liliana Schaefer
Journal:  J Clin Invest       Date:  2010-11-15       Impact factor: 14.808

7.  Can existing drugs approved for other indications retard renal function decline in patients with type 1 diabetes and nephropathy?

Authors:  Alessandro Doria; Monika A Niewczas; Paolo Fiorina
Journal:  Semin Nephrol       Date:  2012-09       Impact factor: 5.299

8.  Myeloid mineralocorticoid receptor activation contributes to progressive kidney disease.

Authors:  Louis L Huang; David J Nikolic-Paterson; Yingjie Han; Elyce Ozols; Frank Y Ma; Morag J Young; Greg H Tesch
Journal:  J Am Soc Nephrol       Date:  2014-04-03       Impact factor: 10.121

9.  Fcγ receptor deficiency attenuates diabetic nephropathy.

Authors:  Virginia Lopez-Parra; Beñat Mallavia; Oscar Lopez-Franco; Guadalupe Ortiz-Muñoz; Ainhoa Oguiza; Carlota Recio; Julia Blanco; Falk Nimmerjahn; Jesus Egido; Carmen Gomez-Guerrero
Journal:  J Am Soc Nephrol       Date:  2012-08-02       Impact factor: 10.121

Review 10.  Inflammation in diabetic nephropathy.

Authors:  Andy K H Lim; Gregory H Tesch
Journal:  Mediators Inflamm       Date:  2012-08-21       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.